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Hypertension in animal models and in humans is associated with a decreased vasodilator response to acetylcholine which
causes vascular relaxation by release of endothelium-derived relaxing factor from the endothelium. Since lowering of blood
pressure, particularly with angiotensin converting enzyme inhibitors, improved the response to acetylcholine we investigated
the effects of brachial artery infusions of ascending dosages of actetylcholine on forearm blood flow before and after 5
months of therapy with the angiotensin converting enzyme inhibitor, cilazapril, in 10 patients with mild to moderate primary
hypertension. Cilazapril decreased blood pressure from 150-8 ± 14-4/98-9 ±4-3 mmHg during placebo to 138-8 ± 15-6/88-6
± 8.9 mmHg (P < 0-01). Brachial artery acetylcholine infusions increased forearm blood flow from 2-95 ± 7-5 to a maxi-
mum of 22-8 ± 11-5 ml.min'1.100 ml'1 forearm tissue and decreased forearm vascular resistance from 48-1 — 34-1 to
6-9 ± 6-9 units before cilazapril. This response did not change after cilazapril therapy. Our findings in patients with primary
hypertension, therefore, do not support the concept that angiotensin converting enzyme inhibition influences endothelium-
dependent vascular relaxation to acetylcholine to a significant degree. Whether this lack of effect on endothelial vasodilator
function is specific for the vascular bed chosen for study or whether it represents a fundamental difference between animal
models and human hypertension remains an important issue to be clarified.
Introduction
Since the landmark description by Furchtgott and
Zawadski'1' that the endothelium is obligatory for the
vasodilator effects of acetylcholine, it has been increasingly
recognised that the endothelial cell monolayer, by virtue of
its location, not only separates blood from underlying vas-
cular muscle and preserves blood fluidity, but is also impor-
tant in the regulation of vascular tone by synthesizing and
releasing highly potent, vasoactive compounds'2-31. The
mechanism responsible for the vasodilator effect of acetyl-
choline has been mostly clarified and most of the activity of
what has been termed endothelium-derived relaxing factor
(EDRF) can be attributed to endothelial generation of
nitric oxide or a substance that spontaneously generates
nitric oxide'4' from 1-arginine'5'. Moreover, it has become
clear that basal release of EDRF, both in animal experi-
ments'6'7' and healthy man'8', is involved in the regulation of
vascular tone. In addition to modulating vascular muscle
tone, the endothelium appears to be a key element in the
early phases of the development of atherosclerosis'91. The
direct study of endothelial integrity is difficult in man,
but endothelial function can be assessed as vasodilator
response to muscarinergic receptor agonists such as acetyl-
choline. Thus, it has been demonstrated that the vascular
action of acetylcholine is independent of prostacyclin pro-
duction or inhibition of adrenergic neurotransmission.
Accordingly, the vascular effects of acetylcholine can be
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ascribed to release of endothelium-derived relaxing fac-
tor'10' and there is evidence that e.g. hypercholesterolaemia
is associated with endothelial dysfunction in human coro-
nary conduit and resistance vessels in vivo which precedes
angiographically visible atherosclerotic lesions in large
coronary arteries'11'. Similar findings were made in forearm
resistance vessels'12'. Likewise, hypertension as another
important risk factor for the development of atherosclero-
sis, is associated with a decreased vasodilator response in
forearm resistance vessels to acetylcholine'1013'. Because
alterations of endothelial function and morphology appear
to coincide'14' and may be markers of early atherosclerotic
vascular changes, the effects of treatment on acetylcholine-
mediated release of endothelium-derived relaxing factor,
as a marker of endothelial function, are worth considering.
Because of experimental evidence that angiotensin con-
verting enzyme inhibitors, but not hydralazine, improved
endothelial vasodilator function in spontaneously hyper-
tensive rats'14', we investigated the effects of cilazapril on
the vasodilator response to acetylcholine in patients with
primary hypertension.
Subjects and methods
Ten patients with a history of mild to moderate hyper-
tension (6 male, 4 female, aged 30 to 55 (mean 46-8 ± 7.2)
years) consented to participate in the study which was
approved by the hospital's ethics committee. Secondary
forms of hypertension were ruled out by a standard work-
upl'5l None of the patients had been treated with calcium
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channel blockers or angiotensin converting enzyme
inhibitors in the preceding 3 months.
STUDY DESIGN
The study was designed as a single-blind, placebo-con-
trolled study lasting 24 weeks. All previous medication was
discontinued and the patient was given placebo tablets
identical in appearance to the active compound. Blood
pressure was always measured in the morning and the
patients were instructed not to take their morning dose on
those days. When casual diastolic blood pressure was
greater than 95 mmHg after 3 weeks of placebo once daily,
the investigation of endothelial function was scheduled 7
days later with the patient still taking placebo. After com-
pleting the first haemodynamic study, patients were given
cilazapril 5 mg once daily for one week and after ensuring
that no adverse clinical or biochemical effects had occurred,
the dose was titrated to 5 mg twice daily for the remainder
of the 20 weeks active treatment period. Additional clinic
visits were scheduled after 4, 8 and 12 weeks and at the end
of the last week of the study period when the study of
endothelial vasodilator function was repeated.
METHODS
Compliance was assessed by counting the number of
returned tablets and was assumed to be good when the
number of tablets taken was within 20% of the theoretical
value for the respective treatment interval. During clinic
visits, blood pressure was assessed using a standard mer-
cury sphygmomanometer and heart rate was counted from
the radial pulse.
All haemodynamic studies were performed in the morn-
ing with the subjects recumbent and comfortably resting
after a light breakfast in a quiet, air-conditioned room at an
ambient temperature of 20-22°C. Under local anaesthesia
(lidocaine 1%) an 18 gauge catheter (Abbocath-T, Abbott,
Sligo, Ireland) was inserted into the left brachial artery for
regional drug infusion and recording of arterial pressure
using a Statham P23 Pb pressure transducer. The subjects
were allowed to rest for 30 min following completion of
instrumentation until basal forearm blood flow, intra-arte-
rial blood pressure and heart rate were recorded. Next,
sodium nitroprusside (0-6 /ig.min.'MOO ml"1 forearm tis-
sue) was infused in the brachial artery and forearm blood
flow measured in the third minute of infusion. After return
of forearm blood flow to baseline (20 to 30 min) the resting
flow was again measured. Finally, acetylcholine (0-8, 10,40
and 160 /jg.miiT'.lOO ml"') was infused over 3 min each'10'
and forearm blood flow measured in the last minute of
each infusion. Blood pressure and heart rate were
recorded immediately after completion of each infusion.
Forearm blood flow was measured bilaterally by venous
occlusion plethysmography1'6!. In short, a mercury in-
silastic strain gauge was placed at the upper third of the
forearm which rested comfortably on a support slightly
above the level of the heart. The strain gauge was coupled
to an electronically calibrated plethysmograph (EC3,
Hokanson, Watassah, WA, U.S.A.). Venous occlusion was
achieved by a blood pressure cuff applied proximal to the
elbow and inflated to 40 mmHg by a rapid cuff inflator
(EC10, Hokanson). The hand was excluded from the circu-
lation by inflating a paediatric blood pressure cuff placed
around the wrist to 50 mmHg above systolic pressure one
minute prior to and during the forearm blood flow mea-
surements, in order to eliminate the unpredictable influ-
ence of arterio-venous shunts in the hand. Experiments
were done on the left (experimental) forearm, while blood
flow measurements on the right (control) arm served as
continuous control. Determinations of forearm blood flow
were made by analysing four to six consecutive recordings
using a digitizing board and suitably programmed com-
puter. The mean value was taken for statistical evaluation.
Forearm vascular resistance was calculated by dividing
mean arterial pressure by forearm blood flow and is
expressed as arbitrary units. The electrocardiogram was
monitored throughout the study.
STATISTICAL ANALYSIS
Results are expressed as means ±SD. One factor analy-
sis of variance was used to test for differences attributable
to the different drugs. Responses to acetylcholine infusions
and the influence of cilazapril were analysed using profile
analysis for repeated measures. The paired and unpaired
Student's t-test and linear regression analysis were
employed as appropriate. A two-tailed f-value of less than
005 was considered to indicate a significant difference. All
calculations were performed using the StatView II
(Abacus Inc, Berkeley. CA, U.S.A.) statistical program.
Results
Angiotensin converting enzyme inhibition by cilazapril
was well tolerated and causal sitting blood pressure
decreased from 150-8 ± 14-4/98-9 ± 4-3 mmHg during
placebo treatment to 138-8 ± 15-6/88-6 ± 8-9 mmHg after
20 weeks of cilazapril (P < 001). Similar decreases were
observed for intra-arterially recorded blood pressures and
heart rate remained unchanged.
The results of the studies of endothelial dependent
(acetylcholine) and independent (sodium nitroprusside)
vasodilatation are depicted in Figs 1 and 2. Sodium nitro-
prusside increased forearm blood flow during placebo
from 2-7 ± 10 to 111 ± 5-4 ml.min.-'.lOO ml"1 and
decreased forearm vascular resistance from 431 ± 21-6 to
120 ± 9-0 units. As shown in Fig. 1, the effect of sodium
nitroprusside on forearm haemodynamics remained
essentially unchanged after cilazapril therapy. Brachial
artery acetylcholine infusions increased forearm blood
flow from 2-95 ± 1-5 to a maximum of 22-8 ± 11-5
ml.min."'.100 ml"' and decreased forearm vascular resis-
tance from 481 ± 34-1 to 6-9 ± 6-9 units. As shown in Fig.
2, this response did not differ after cilazapril therapy.
Individual changes in vascular responsiveness to acetyl-
choline were not related to age, height of blood pressure
before treatment or cilazapril-induced decreases of either
systolic or diastolic blood pressure. Increases in forearm
blood flow to sodium nitroprusside and acetylcholine on
placebo were significantly correlated with values observed
after cilazapril therapy (r = 0-61 and r = 0-68, both
P < 0-05).
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Figure I Response of forearm resistance vessels to brachial artery infusion of sodium nitroprusside in
10 hypertensive patients. The response of forearm blood flow is depicted in the left panel, the reduc-
tion of calculated forearm vascular resistance in the right panel. Open bars represent results obtained
at the end of the placebo period and hatched bars after 5 months of therapy with cilazapril 5 mg b.i.d.
Values are means ± standard deviation.
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2 Response of forearm resistance vessels to brachial artery infusion of ascending dosages of
acetylcholine in 10 hypertensive patients. The response of forearm blood flow is depicted in the left
panel, the reduction of calculated forearam vascular resistance in the right panel. There was no differ-
ence in the vascular response to acetylcholine when comparing results obtained at the end of the placebo
period (open bars) and those after 5 months of therapy with cilazapril 5 mg b.i.d. (hatched bars). Values
are means ± standard deviation.
Discussion
Arterial hypertension in humans and animal models of
hypertension is associated with structural and functional
changes of the arterial system, including the resistance ves-
sels which are responsible for the main haemodynamic dis-
turbance found in hypertension, e.g. elevated peripheral
vascular resistance'171. Folkow and co-workers1'7' were the
first to draw attention to the finding that hypertensive resis-
tance vessels have an altered structural design due to an
increase in medial thickness resulting in an increased wall
to lumen ratio, rendering the vessels more responsive to
vasoconstrictor stimuli. Recent evidence suggests that
actual medial hypertrophy in hypertensive resistance arter-
ies can only explain a fraction of the encroachment of the
lumen observed in stroke prone spontaneously hyperten-
sive rats and that the greater part of this disturbance is due
to a reduction in external diameter, a finding termed
'remodelling''18'. Similar considerations appear to apply to
human primary hypertension1'9'.
Several functional aspects of regulation of vascular resis-
tance also appear to be disturbed in human hypertension,
including a greater sympathetic nervous system contribu-
tion to resting arteriolar tone'1620', enhanced calcium-influx
dependent vasoconstriction'21-22' and, more recently,
impaired vasodilatation in response to muscarinergic stim-
ulation'1013'. The latter response in the human forearm is
mediated by endothelium-derived relaxing factor and not
by interference with neural release of catecholamines or
endothelial release of prostacyclin'10'. Therefore, human
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hypertensive resistance vessels appear to resemble animal
models of hypertension in which a diminished vasodilator
response of large conduit arteries to muscarinergic stimu-
lation is commonly observed in vitro'23"27'. In contrast to
findings in humans, microvascular relaxation in response to
acetylcholine was normal in salt-sensitive hypertensive
Dahl rats'28' and rabbits with cellophane wrap-induced
hypertension'29'. Interpretation of results is further compli-
cated by the finding that the degree of endothelial dysfunc-
tion varied in differing vascular beds in spontaneously
hypertensive rats'30'. Interestingly, antihypertensive ther-
apy and reversal of hypertension126-"' normalized disturbed
endothelial vasodilator function in animal models of
hypertension. The observation that the angiotensin con-
verting enzyme inhibitor cilazapril. but not the direct act-
ing vasodilator hydralazine'14', improved endothelium-
mediated vasodilator responses to muscarinergic stimula-
tion in rat models of hypertension, raised the possibility
that mechanisms other than blood pressure lowering per se
are important in that respect. In view of the proposed key
role of the endothelium in the development of atheroscle-
rosis and its vascular complication'9', and considering that
an impairment of acetylcholine-induced coronary artery
dilation is one of the earliest findings in subjects with risk
factors for. but no angiographic evidence of, coronary ath-
erosclerosis'"', the normalization of endothelial function
by angiotensin converting enzyme inhibition in animals
might point to a potentially important aspect of antihyper-
tensive therapy which so far has received little attention in
humans.
The present study investigated the effects of 5 months
antihypertensive monotherapy with cilazapril on acetyl-
choline-mediated relaxation of forearm resistance vessels
which exhibit reduced responsiveness to. or a diminished
release of, endothelium-derived relaxing factor in response
to muscarinergic stimulation''"'3'. Cilazapril effectively
lowered blood pressure, confirming its antihypertensive
properties when given in monotherapy'32-131. Despite the
pronounced decrease in blood pressure, we were unable to
find an improvement in the vascular response to acetyl-
choline. Responses to both endothelium-dependent. e.g.
acetylcholine, and endothelium-independent, e.g. sodium
nitroprusside, relaxation obtained before and after cilaza-
pril therapy were closely correlated attesting to the repro-
ducibility of the method employed. Therefore, these results
are at variance with previous reports of the effects of anti-
hypertensive therapy on endothelial function in various
animal models of hypertension'14-26-31'.
There is no ready explanation for this discrepancy, but
several aspects need to be considered. Thus, therapy lasted
5 months which may not be enough to reverse potential
changes brought about by long-standing hypertension.
However, in spontaneously hypertensive rats, cilazapril
improved acetylcholine-mediated vasodilatation after 4
days of therapy, suggesting that endothelial function can be
influenced within a short time span'14'. The disturbed
endothelial response to acetylcholine in hypertensive Dahl
rats has also been found to depend upon the magnitude of
blood pressure elevation'251. Accordingly, it might be
argued that in patients with more severe hypertension a
more pronounced endothelial impairment might have
been improved by therapy. On the other hand, captopril,
but not hydralazine, had a marked potentiating effect on
acetylcholine-induced relaxations of aortic rings from nor-
motensive rats'34'. Interestingly, the angiotensin converting
enzyme inhibitor, enalapril, did not affect the vascular
acetylcholine response in that study. Thus, it appears
unlikely that the degree of hypertension was a deciding fac-
tor in the inability of cilazapril to influence the response of
the forearm vasculature to acetylcholine. More obvious is
the fact that most of the animal and in-vitro data were
obtained in vascular preparations from large conduit arter-
ies, while the present data reflect the behaviour of resis-
tance vessels mostly supplying skeletal muscle. This may, of
course, reflect a fundamental difference in the response of
the endothelium in different sections of the arterial tree to
lowering of blood pressure. Finally, species differences
regarding their ability to change endothelial function in
response to antihypertensive therapy cannot be excluded
as an important factor for the discrepancy between our
findings and animal experiments.
In conclusion, our findings obtained in vivo in patients
with primary hypertension do not support the concept that
angiotensin converting enzyme inhibition, despite a con-
siderable decrease in blood pressure, influences endothe-
lium-dependent vascular relaxation to acetylcholine to a
significant degree. Whether this lack of effect on endothe-
lial vasodilator function is specific for the vascular bed
chosen for study, e.g. mostly resistance vessels supplying
forearm skeletal muscle, or whether it represents a funda-
mental difference between animal models and human
hypertension remains an important issue to be clarified.
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